Key statistics
On Friday, Myriad Genetics Inc (MYD:HAM) closed at 24.20, -6.20% below its 52-week high of 25.80, set on Sep 17, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.00 |
---|---|
High | 25.00 |
Low | 24.20 |
Bid | 24.60 |
Offer | 25.00 |
Previous close | 25.40 |
Average volume | 0.00 |
---|---|
Shares outstanding | 90.82m |
Free float | 88.94m |
P/E (TTM) | -- |
Market cap | 2.51bn USD |
EPS (TTM) | -1.80 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 16:25 BST.
More ▼
Announcements
- Myriad Genetics to Share New Data Highlighting Genetic Testing Advancements at 2024 National Society of Genetic Counselors Annual Conference
- Myriad Genetics to Host Investor Event on October 9, 2024
- Myriad Genetics to Participate in Two Upcoming Investor Healthcare Conferences
- Myriad Genetics Reports Strong Second Quarter 2024 Financial Results, including 15% Revenue Growth Year-Over-Year; Raises 2024 Financial Guidance and Long-Term Revenue Growth Target to 12%
- Myriad Genetics Advances International Reorganization and Completes Sale of EndoPredict Business to Eurobio Scientific
- Myriad Genetics Appoints Jennifer Fox as Chief Legal Officer
- Myriad Genetics to Release Second Quarter 2024 Financial Results on August 6, 2024
- What We Don’t Know Can Hurt: New Cancer Risk Survey from Myriad Genetics Reveals Serious Knowledge Gaps About Breast Density and Cancer Risk
- Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
- Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
More ▼